Cyclo Therapeutics, Inc. (CYTH)
Largest Insider Buys in Sector
CYTH Stock Price History Chart
CYTH Stock Performance
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company …
Insider Activity of Cyclo Therapeutics, Inc.
Over the last 12 months, insiders at Cyclo Therapeutics, Inc. have bought $0 and sold $0 worth of Cyclo Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cyclo Therapeutics, Inc. have bought $2.08M and sold $522,370 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,000,000 shares for transaction amount of $5M was made by Rafael Holdings, Inc. (10 percent owner) on 2023‑08‑01.
List of Insider Buy and Sell Transactions, Cyclo Therapeutics, Inc.
| 2023-08-01 | 10 percent owner | 4M 23.6663% | $1.25 | $5M | -2.41% | |||
| 2023-04-20 | Chief Executive Officer | 299,402 2.7233% | $0.71 | $212,575 | +105.99% | |||
| 2023-04-20 | director | 59,881 0.5447% | $0.71 | $42,516 | +105.99% | |||
| 2023-04-20 | director | 59,881 0.5447% | $0.71 | $42,516 | +105.99% | |||
| 2023-04-20 | Chief Operating Officer | 29,941 0.2723% | $0.71 | $21,258 | +105.99% | |||
| 2022-09-21 | director | 5,000 0.0594% | $1.76 | $8,800 | -14.29% | |||
| 2022-05-20 | 12 0.0001% | $2.00 | $24 | -8.59% | ||||
| 2022-05-16 | Chief Operating Officer | 3,000 0.0357% | $2.12 | $6,354 | -12.80% | |||
| 2022-04-28 | Chief Operating Officer | 635 0.007% | $2.50 | $1,588 | -30.00% | |||
| 2022-03-29 | 10,000 0.1167% | $2.73 | $27,300 | -29.50% | ||||
| 2022-02-07 | Chief Executive Officer | 10,334 0.1229% | $3.58 | $36,996 | -41.90% | |||
| 2022-01-24 | director | 2,000 0.0246% | $3.75 | $7,500 | -41.71% | |||
| 2022-01-19 | Chief Executive Officer | 5,000 0.0572% | $3.89 | $19,450 | -47.28% | |||
| 2022-01-19 | director | 1,132 0.0133% | $4.00 | $4,528 | -47.28% | |||
| 2022-01-14 | director | 3,868 0.0434% | $4.00 | $15,472 | -49.76% | |||
| 2021-12-15 | Chief Executive Officer | 5,000 0.0758% | $3.89 | $19,450 | -45.04% | |||
| 2021-12-15 | director | 3,000 0.0456% | $3.90 | $11,700 | -45.04% | |||
| 2021-12-10 | director | 5,000 0.0792% | $4.40 | $22,000 | -48.85% | |||
| 2021-12-03 | director | 864 0.0135% | $4.75 | $4,104 | -52.83% | |||
| 2021-12-02 | Chief Executive Officer | 5,000 0.0775% | $4.93 | $24,650 | -54.81% |
Insider Historical Profitability
| NOVIT, L.P. | 10 percent owner | 21517582 74.7967% | $0.62 | 4 | 0 | |
| STRATTAN CE RICK | 19877647 69.0961% | $0.62 | 2 | 5 | ||
| Rafael Holdings, Inc. | 10 percent owner | 6514970 22.6465% | $0.62 | 1 | 0 | |
| Farnan Joseph J Jr | director | 1340000 4.6579% | $0.62 | 2 | 0 | |
| FINE N SCOTT | Chief Executive Officer | 444402 1.5448% | $0.62 | 17 | 0 | <0.0001% |
Institutional Investor Ownership
| EPIQ Capital Group | $1.19M | 2.98 | 853,815 | New | +$1.19M | 0.48 | |
| Founders Fund V Management Llc | $668,184.00 | 1.68 | 480,708 | 0% | +$0 | 0.32 | |
| The Vanguard Group | $551,355.00 | 1.39 | 396,658 | +11.66% | +$57,594.69 | <0.0001 | |
| Geode Capital Management | $222,109.00 | 0.56 | 159,749 | +5.04% | +$10,666.86 | <0.0001 | |
| Founders Fund Vi Management Llc | $152,932.00 | 0.39 | 110,023 | 0% | +$0 | 2.02 |